On April 3, 2022, the "Sixth Healthcare Investment Excellence List" sponsored by Haoyue Capital, an industrial investment bank focusing on China's medical and health care, was officially released. Hopstem won the honor of "Best Biopharmaceutical Company of the Year" in Excellence List.

Hopstem is an innovative research and development enterprise dedicated to providing stable, safe, effective, and affordable iPSC cell therapy products for patients around the world. Hopstem has always been adhering to the mission of benefiting patients with innovative iPSC cell therapy. In the future, Hopstem will further accelerate the development of more clinical products of great value for patients.